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ABSTRACT
Background: Vitamin K antagonist (VKA) to prevent thromboembolism in non-valvular atrial 
fibrillation (NVAF) patients has limitations such as drug interaction. This study investigated 
the clinical characteristics of Korean patients treated with VKA for stroke prevention and 
assessed quality of VKA therapy and treatment satisfaction.
Methods: We conducted a multicenter, prospective, non-interventional study. Patients with 
CHADS2 ≥ 1 and treated with VKA (started within the last 3 months) were enrolled from April 
2013 to March 2014. Demographic and clinical features including risk factors of stroke and 
VKA treatment information was collected at baseline. Treatment patterns and international 
normalized ratio (INR) level were evaluated during follow-up. Time in therapeutic range (TTR) 
> 60% indicated well-controlled INR. Treatment satisfaction on the VKA use was measured by 
Treatment Satisfaction Questionnaire for Medication (TSQM) after 3 months of follow-up.
Results: A total of 877 patients (age, 67; male, 60%) were enrolled and followed up for one 
year. More than half of patients (56%) had CHADS2 ≥ 2 and 83.6% had CHA2DS2-VASc ≥ 2. 
A total of 852 patients had one or more INR measurement during their follow-up period. 
Among those patients, 25.5% discontinued VKA treatment during follow-up. Of all patients, 
626 patients (73%) had poor-controlled INR (TTR < 60%) measure. Patients' treatment 
satisfaction measured with TSQM was 55.6 in global satisfaction domain.
Conclusion: INR was poorly controlled in Korean NVAF patients treated with VKA. VKA users 
also showed low treatment satisfaction.
Keywords: Atrial Fibrillation; Anticoagulation; Vitamin K Antagonist; INR Control; 
Satisfaction
INTRODUCTION
The prevalence of atrial fibrillation (AF), the most common sustained arrhythmia, was 0.7% 
in adults 40 years of age or older and 2.1% in adults 65 years or older in Korea.1 As reported 
in several precedent studies, an increase in age is a risk factor in patients with AF,2 thus as the 
population is aging, the incidence rate of AF is likely to increase and hospital utilization rate 
and the mortality rate are expected to increase as well. In addition, AF is a disease that becomes 
a risk factor for stroke and systemic embolism.3 In particular, strokes accompanied by AF 
showed a higher mortality rate and hospitalization costs than strokes not accompanied by AF.4-
6 According to the results of a study of the ratio of patients immobilized due to stroke, patients 
with strokes accompanied by AF showed a higher invalidity rate than patients with strokes not 
accompanied by AF (41.2% vs. 23.7%, P < 0.0005).5 Likewise, various studies showed that the 
prognosis is much worse when accompanied by AF than when not accompanied by AF.
The 2014 American Heart Association (AHA)/American College of Cardiology (ACC)/Heart 
Rhythm Society (HRS) guidelines recommend medicines for preventive treatment according 
to the risk of a stroke for a patient with AF.7 However, many study results showed that patients 
are receiving treatment that does not correspond to the treatment guidelines or have even 
received no treatment at all in real-world clinical scenes. According to a systematic literature 
review of 54 studies reported from 1998 to 2008,8 less than 70% of patients were treated with an 
anticoagulant even after they were determined to be in a high-risk group by the CHADS2 score 
used to determine the stroke risk level, and 2/3 of the studies reported that less than 60% of the 
patient group with a history of stroke or transient ischemic attack was treated.
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Vitamin K antagonist (VKA), which is considered to be a standard of care among the 
anticoagulant medicines to prevent strokes in patients with AF, has a very narrow therapeutic 
range, thus regular monitoring is required to avoid potential adverse events.9 However, 
according to the results of the Korean Patients with Atrial Fibrillation (KORAF) study 
conducted on AF patients in Korea, the international normalized ratio (INR) was adequately 
controlled in only about 40% of patients treated with VKA.10 A comparative study on severe 
adverse events (SAE) such as death, occurrence of thrombosis related to an anticoagulant, 
and additional administration of heparin between a patient group that had a poorly 
controlled INR value and a patient group that had a well-controlled INR value revealed that 
the SAE incidence rate of the patient group that had a poorly controlled INR was higher than 
that of the patient group that had a well-controlled INR.11 Thus, INR control is important 
when using a VKA.
The purpose of this study is to investigate the clinical and demographic characteristics of 
Korean patients with non-valvular AF treated with VKA for stroke prevention and determine 
the ratio of patients who have a well-controlled INR, and also evaluate the difference between 
the group that has a well-controlled INR and the group that has a poorly controlled INR. In 
addition, we tried to identify the patients' satisfaction with VKA treatment, continuation 
rate, and reasons for discontinuation of treatment.
METHODS
Study subjects
This is a Korean Atrial Fibrillation Investigation II (KORAFII) study with a multicenter, 
prospective, non-interventional design. The patients were enrolled at 20 cardiology clinics 
nationwide from April 2013 to March 2014. The study subjects were selected according to 
the following inclusion criteria: 1) Patients who are 20 years of age or over and diagnosed 
with non-valvular AF, 2) Patients who newly start VKA treatment (Daehwa Warfarin 2 mg 
or 5 mg Tab, Daehwa Pharmaceutical, Hoengseong-eup, Korea; Jeil Warfarin 5 mg Tab, 
Jeil Pharmaceutical Co., Seoul, Korea; Kufarin 2 mg or 5 mg Tab, Hana Pharm Co., Seoul, 
Korea) to prevent a stroke and systemic embolism or have started VKA treatment within the 
last 3 months, 3) Patients with CHADS2 ≥ 1, 4) Patients for whom regular INR monitoring is 
considered possible by the researchers, 5) Patients for whom one-year follow-up is possible, 
and 6) Patients who can understand the description of the written consent and the consent 
form and submit the consent form.
Calculation of number of subjects
According to the related literature, about 50%12 of the patients treated with VKA 
discontinued VKA administration within 1 year, and thus received inappropriate care. Among 
the remaining 50% of patients who continued to receive VKA administration, about 60%1 
(i.e., 30% of total patients) also received inappropriate care because their INR level failed to 
reach level 2–3. In other words, the adequate control ratio of INR for patients treated with 
VKA was about 20% at the maximum, and the number of final target cases calculated at 
95% confidence level with a margin of error of ± 2.5% using the PASS 2008 program (NCSS, 
Kaysville, UT, USA)13 was approximately 1,000.14,15 In this study, a final 877 patients were 
enrolled according to their voluntary consent to participate and the selection criteria from 
among patients treated with VKA in all participating medical institutions.
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Study data and follow-up
In this study, the characteristics of patients and VKA usage patterns were identified by following 
up for 12 months after the patient enrollment date, and the data collected to investigate the 
INR control, VKA treatment satisfaction and so on were largely classified into investigation 
variables at the baseline and at the follow-up point. The following variables were investigated 
as the baseline characteristics of patients: 1) Demographic/clinical characteristics (sex, age, 
body mass index [BMI], date diagnosed with non-valvular AF/AF type) and 2) stroke and 
hemorrhage risk factors (components of CHA2DS2-VASc and HAS-BLED scores). In addition, 
demographic variables that could not be gathered by the medical record review (smoking, 
drinking, underlying diseases, occupation and education) were collected with a patient 
questionnaire. The VKA treatment patterns (date/values of INR measurement, continuation 
of VKA prescription, etc.) were collected by the medical record review during the follow-up 
period, and treatment satisfaction was investigated with two types of questionnaires (a simple 
questionnaire and the Treatment Satisfaction Questionnaire for Medication, or TSQM).
Degree of INR control
The degree of INR control (well controlled or poorly controlled) was identified by 12-month 
follow-up and assessed by the proportion of tests in a range method. Time in therapeutic range 
(TTR) was defined as the ratio of the days showed the optimal INR level (2.0–3.0) to total visit 
days during 12 months. And the well-controlled INR group was defined as patients who showed 
TTR in equal to or more than 60%. The poor-controlled INR group was defined as patients 
other than well-controlled INR. The cut-off value, 60%, was defined by the investigators using 
insight based on extensive clinical experience. The INR values used in the analysis were from 
the patients whose INR was measured at least once during the 12-month follow-up.
VKA treatment satisfaction
The treatment satisfaction of patients was assessed by two types of self-completed treatment 
satisfaction surveys of all patients. A simple questionnaire simply asked if the patient 
was satisfied with the treatment and investigated the cause and presented the results in a 
percentage if the patient was not satisfied. The TSQM, which was composed of four domains 
(effectiveness, side effects, convenience, and global) was conducted as another survey tool. 
The score, which is from 0 to 100, is graded by domain, and a higher score means greater 
satisfaction. Multiple linear regressions were conducted to find the variables that affected 
satisfaction for each TSQM domain.
Definition of time to reach optimal dose
The time to reach the optimal dose was defined as the time from the baseline point to the initial 
point (day) at which the INR values were “consecutively” maintained within 2–3 scores twice or 
more. The subjects whose INR values were not consecutively maintained within 2–3 scores twice 
or more at each point of value measurement were processed as censored, and the time from the 
baseline to the final INR measurement date was considered to be the censored observation time. 
The Kaplan-Meier survival function was used to assess the time when they reached the optimal dose.
Statistical analysis
Baseline characteristics of study subjects
Continuous data was displayed by means, standard deviations or medians and was analyzed 
using Student's t-test or analysis of variance to compare the characteristics by group. 
Categorical data was displayed by absolute frequency and rate and was analyzed using a χ2 test 
or Fisher's exact test to compare the characteristics by group.
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Ethics Statement
This study was approved by the Institutional Review Board (IRB) of Korea University Anam 
Hospital (IRB No. AN12250-001). All patients provided their informed consent prior to their 
enrollment in the study.
RESULTS
Baseline characteristics
A total of 877 patients with NVAF (mean age, 67.7; males, 60.1%) were enrolled in this study. 
The mean CHADS2 scores of the patients was 1.85, and the ratio of high-risk group patients 
with scores of 2 or higher was more than half (56.0%). The mean CHA2DS2-VASc score was 
2.9, and the ratio of high-risk group patients with scores of 2 or higher was considerable 
(83.6%). The mean HAS-BLED score was 1.5, and the ratio of high-risk group patients with 
scores of 3 or higher was 7.7% (Table 1).
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Table 1. Baseline characteristics
Characteristics Value (n = 877)
Sex, male 527 (60.1)
Age, yr 67.68 (10.1)
BMI 24.80 (3.3)
NVAF duration,a mon 18.17 (33.9)
Type of NVAF
First diagnosed 94 (10.7)
Paroxysmal 271 (30.9)
Persistent 346 (39.5)
Long-standing persistent 43 (4.9)
Permanent 82 (9.4)
Unknown 41 (4.7)
Mental comorbid conditions, yes 41 (4.7)
Employment, yes 316 (36.2)
Alcohol use
Non-drinker 382 (43.6)
Past drinker 218 (24.9)
Current drinker 277 (31.6)
Smoking
Non-smoker 516 (58.8)
Past smoker 281 (32.0)
Current smoker 80 (9.1)
Education
No education 67 (7.7)
≤ Elementary school 216 (24.9)
≤ Middle school 133 (15.3)
≤ High school 243 (28.0)
≤ University 172 (19.8)
≥ Post-graduation school 38 (4.4)
CHADS2 score 1.85 (0.9)
CHADS2 score ≥ 2 491 (56.0)
CHA2DS2-VASc score 2.94 (1.4)
CHA2DS2-VASc score ≥ 2 733 (83.6)
HAS-BLED score 1.48 (0.7)
HAS-BLED score ≥ 3 54 (7.7)
Data are presented as mean (standard deviation) or number (%).
BMI = body mass index, NVAF = non-valvular atrial fibrillation.
aUnknown: 149 cases.
Anticoagulation quality
During the follow-up period, among 852 patients whose INR was measured more than once, 
the cases in which VKA was discontinued accounted for 18.5%. Among the patients to which 
VKA was discontinued, 60.1% were changed to antiplatelets, and the medicine was changed 
to non-vitamin K antagonist oral anticoagulants (NOAC) in 37.3% among them. The number 
of patients who had a well-controlled INR were 226 (26.5%) (Table 2). Also, 335 patients 
newly started taking VKA and 215 among them maintained the optimal dose twice in a row 
during the follow-up period. The median time to reach the optimal dose twice consecutively 
was 154 days (95% confidence interval [CI], 133–179 days) (Fig. 1).
The CHA2DS2-VASc score was higher in the group that had a well-controlled INR than in the 
group that had a poorly controlled INR (3.2 vs. 2.9, P < 0.001). Patients in the group that had 
a poorly controlled INR were younger than the group that had a well-controlled INR (66 vs. 72 
years, P < 0.001) and had a higher HAS-BLED score (1.5 vs. 1.4, P = 0.03) (Table 3).
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Table 2. VKA treatment and INR level of the patients who had INR measurement ≥ 1 during their follow up period
Treatment/level Value (n = 852)
VKA treatment
Continuation 635 (74.5)
Switching to other drugs 158 (18.5)
Switching to aspirin 59 (37.3)
Switching to clopidogrel 21 (13.3)
Switching to aspirin + clopidogrel 15 (9.5)
Switching to NOAC 59 (37.3)
Switching to others 4 (2.5)
No switching 59 (6.9)
INR level, at baseline 1.89 ± 0.96
INR level, during follow-up 1.97 ± 0.64
No. of INR measurements during follow-up 5.98 ± 3.29
Patients with TTR ≥ 60 226 (26.5)
Data are presented as mean (standard deviation) or number (%).
VKA = vitamin K antagonist, INR = international normalized ratio, NOAC = non-vitamin K antagonist oral 
anticoagulants, TTR = time in therapeutic range.
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Fig. 1. Kaplan-Meier curve of time to optimal dose for VKA treatment with two-consecutive dose maintaining. 
VKA = vitamin K antagonist, CI = confidence interval.
Treatment satisfaction
The patients' satisfaction with VKA treatment was investigated with a total of 730 patients 
(mean age, 67.9 years; males, 59.0%), and the mean of each domain of the TSQM was as 
follows: effectiveness (57.9 ± 12.0), side effects (96.3 ± 11.6), convenience (64.0 ± 13.5), 
and global satisfaction (55.6 ± 14.5) (Table 4). According to the simple questionnaire on 
treatment satisfaction, 91 patients (12.5%) replied that they were not satisfied with VKA 
treatment. The main reasons for dissatisfaction were restrictions on diet or alcohol intake 
(36.3%), frequent hospital visits for blood tests (18.7%), and side effects such as bleeding or 
bruising (16.5%) (Fig. 2).
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Table 3. Factors related with INR control (n = 852)
Characteristics WC PC P value
Sex, male 131 (58.0) 381 (60.9) 0.4457a
Age, yr 71.77 (7.78) 66.20 (10.42) < 0.0001b
BMI 24.69 (3.32) 24.87 (3.29) 0.5242b
NVAF duration, mon 21.03 (40.42) 17.44 (31.59) 0.8384c
Type of NVAF 0.8887a
First diagnosed 27 (12.0) 65 (10.4)
Paroxysmal 68 (30.1) 195 (31.2)
Persistent 85 (37.6) 250 (39.9)
Long-standing persistent 13 (5.8) 30 (4.8)
Permanent 24 (10.6) 56 (9.0)
Unknown 9 (4.0) 30 (4.8)
Mental co-morbid conditions, yes 14 (6.2) 25 (4.0) 0.1747a
Employment, yes 56 (24.9) 247 (39.7) < 0.0001a
Alcohol use 0.0775a
Non-drinker 111 (49.1) 256 (40.9)
Past drinker 55 (24.3) 162 (25.9)
Current drinker 60 (26.6) 208 (33.2)
Smoking 0.0577a
Non-smoker 140 (62.0) 356 (56.9)
Past smoker 74 (32.7) 204 (32.6)
Current smoker 12 (5.3) 66 (10.5)
Education 0.9384a
No education 18 (8.0) 48 (7.8)
≤ Elementary school 52 (23.1) 157 (25.4)
≤ Middle school 34 (15.1) 94 (15.2)
≤ High school 62 (27.6) 173 (28.0)
≤ University 47 (20.9) 123 (19.9)
≥ Post-graduation school 12 (5.3) 24 (3.9)
CHADS2 score 1.92 (0.89) 1.83 (0.97) 0.0637c
CHA2DS2-VASc score 3.21 (1.21) 2.85 (1.43) 0.0002b
HAS-BLED score 1.41 (0.63) 1.52 (0.66) 0.0292c
VKA dosage, mg/day 19.51 (7.61) 19.36 (9.84) 0.8190b
VKA treatment 0.0003a
Continue 189 (83.6) 446 (71.3)
Discontinued & switching 22 (9.7) 446 (71.3)
Discontinued & no switching 15 (6.6) 44 (7.0)
Data are presented as mean (standard deviation) or number (%).
INR = international normalized ratio, WC = well-controlled, PC = poor-controlled, BMI = body mass index,  
NVAF = non-valvular atrial fibrillation, VKA = vitamin K antagonist.
aP value calculated by χ2 test; bP value calculated by Student's t-test; cP value calculated by Mann-Whitney's U test.
Table 4. TSQM subscale scores (n = 730)
TSQM score Effectiveness Side effects Convenience Global satisfaction
Mean (SD) 57.9 (12.0) 96.3 (11.6) 64.0 (13.5) 55.6 (14.5)
Median (Min, Max) 55.6 (16.7, 100) 100 (0, 100) 66.7 (16.7, 100) 57.1 (7.1, 100)
TSQM = treatment satisfaction questionnaire for medication, SD = standard deviation.
In multivariable linear regression analysis based on the univariate results and clinically selected 
variables, the associations with lower effectiveness score and global satisfaction score were 
shown in long standing persistent AF compared to that of first diagnosed AF (β = −5.6, P < 0.05; 
β = −6.8, P < 0.05). In addition, the presence of a comorbid mental condition compared to 
none was associated with lower effectiveness score (β = −4.5, P < 0.05). The higher convenience 
score was related to the higher VKAs dose (β = 1.7, P < 0.01), and high level education of at least 
post-graduation school compared to no education (β = 7.4, P < 0.05). Side-effect score was not 
related to any of the factors (Table 5).
DISCUSSION
The results of this study showed that the elderly and males comprised high proportions of 
non-valvular AF patients, the same as the study previously conducted on Korean patients 
with AF.1 The ratio of high-risk patients with a mean CHA2DS2-VASc score of 2 or higher was 
83.6%, which was comparable to the fraction (85.4%) in the pre-direct oral anticoagulant 
period (January 2011 to July 2013) in the previous study.16 On the other hand, the percentage 
of high-risk patients with a HAS-BLED score of 3 or higher was 7.7%, which was somewhat 
lower than the percentage (32.3%) in the previous study.16
During the follow-up observation period, the percentage of patients that had well-controlled 
INR was 26.5%, which was within the 16.7% (Asia)–49.4% (Europe) range in the GARFIELD-AF 
study,17 a worldwide observational prospective study. The INR was especially poorly controlled 
in Asia compared to other regions, which is interpreted as being due to the characteristics of AF 
patients in Asia who have lower INR values than patients in other regions.18
The reason why the CHA2DS2-VASc score was higher in the group where the INR was 
more well-controlled than the group that was not might be because the doctors paid more 
attention to INR control for the people to whom a stroke could cause more harm.19 The 
group where the INR was well-controlled had a higher HAS-BLED score, but the difference 
was not clinically significant. In addition, the reason why INR is better controlled in the 
elderly is perhaps because the doctors prescribed medicine more carefully, since the elderly 
group was reported to be the group with a high risk of having a stroke.1
Patients' satisfaction with VKA treatment was low overall in all domains except for side 
effects. In particular, comparing the global satisfaction score to the score of patients with 
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Fig. 2. Dissatisfaction with the VKA use. 
VKA = vitamin K antagonist.
other diseases (hypertension [72.1],20 epilepsy [68.4],21 and coronary heart disease [69.2]22) 
measured by TSQM, the measurement tool like ours, it showed a much lower satisfaction 
level. The reasons why the patients who replied to the simple question of satisfaction with the 
treatment that they were not satisfied were restrictions on diet or alcohol intake,23-27 frequent 
hospital visits for blood tests28,29 and occurrence of bleeding,30-32 which were the same as 
those reported in previous studies.
The long duration of AF was a variable related to the low effectiveness of VKA treatment and 
overall satisfaction, and patients with co-morbid mental conditions showed low effectiveness 
of treatment. The higher the education level was and the higher the VKA prescription dosage 
was, the higher the convenience of VKA administration became. According to A PREFER in 
the AF Registry sub-study,33 the patients who switched to NOAC from VKA showed lower 
incidence rates of hypertension and heart valve dysfunction, fewer cases of combined therapy 
with antiplatelet/anti-inflammatory agents, and lower CHA2DS2-VASc scores. As shown in 
these results, it is likely that patients who had AF for a long time and were taking VKA had a 
more sensitive response to the effectiveness of treatment because the treatment effectiveness 
of VKA was lower than that of NOAC. In addition, there were many cases in which patients 
who had low anxiety/depressive traits expressed dissatisfaction with VKA and switched to 
another medicine.33
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Table 5. Multivariable linear regression analysis for TSQM scoresa
Characteristics Effectiveness Side effects Convenience Global satisfaction
β Pb β Pb β Pb β Pb
Sex, male 0.07 0.95 −0.48 0.69 0.93 0.62 0.08 0.95
Age, yr 0.03 0.60 −0.01 0.85 0.09 0.31 0.02 0.79
BMI −0.09 0.65
Type of NVAF
Paroxysmal 1.72 0.29 2.21 0.16 −0.24 0.90
Persistent 0.69 0.66 2.83 0.06 1.65 0.38
Long-standing persistent −5.56 0.02 −0.72 0.76 −6.77 0.02
Permanent 2.00 0.32 0.262 0.90 1.43 0.56
Unknown −2.29 0.36 −2.19 0.36 −3.88 0.20
Mental co-morbid conditions, yes −4.48 0.04
Alcohol use
Past drinker −0.80 0.50
Current drinker 2.15 0.06
Smoking
Past smoker 2.92 0.08
Current smoker 1.46 0.57
Education
≤ Elementary school −2.48 0.16 1.68 0.32 0.09 0.97 −0.22 0.92
≤ Middle school 0.16 0.94 1.18 0.53 3.02 0.24 1.96 0.41
≤ High school −0.71 0.70 3.29 0.07 −1.35 0.57 −1.56 0.49
≤ University −1.86 0.36 −1.04 0.59 1.39 0.59 −3.06 0.21
≥ Post-graduation school 0.95 0.73 3.71 0.16 7.45 0.04 1.37 0.68
CHA2DS2-VASc Score 0.11 0.81 0.07 0.87 0.13 0.84 0.01 0.99
HAS-BLED Score 1.58 0.12
VKA dosage, mg/day 1.71 < 0.01
Well controlled INR −0.66 0.63
VKA Tx.
Continue 1.50 0.46 2.66 0.30
Discontinue & switching to other antithrombotics −2.55 0.26 0.20 0.94
TSQM = treatment satisfaction questionnaire for medication, BMI = body mass index, NVAF = non-valvular atrial fibrillation, VKA = vitamin K antagonist,  
INR = international normalized ratio.
aAdjusted variables were selected from univariate results (P < 0.1) and other clinically selected variables by physicians; bP value calculated by multiple linear 
regression analysis. Reference category: sex (female), type of NVAF (first diagnosed), mental co-morbid conditions (No), alcohol use (non-drinker), smoking 
(non-smoker), education (no education), VKA treatment (discontinue & no switching to other antithrombotics), INR (poor controlled).
The limitations of this study are as follows: First, the participants in this study were patients 
who took part in it voluntarily, and the data was gathered at the time of their visit to the 
hospital as outpatients during the one-year follow-up period. Thus, the time of visit was 
different for each patient during the follow-up period. Second, unmeasured variables in this 
study were not considered as the potential confounders.
In spite of these limitations, in the real-world practice of Korea, INR was poorly controlled 
in patients. The principal reasons for dissatisfaction about VKA therapy were dietary 
restrictions, and regular monitoring etc. The global satisfaction score was lower among VKA 
users with NVAF than those of previous studies on treatment satisfaction in other diseases. 
Alternative oral anticoagulant therapy should be considered for patients with NVAF for 
enhancing treatment satisfaction and doing INR control well.
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